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Abstract
Matrix metalloproteinases (MMPs) are implicated in tumour invasion and metastasis. We report the first use of an MMP
inhibitor to treat unresectable cholangiocarcinoma. Four men with stage IV cholangiocarcinoma received oral Marimastat
(10 mg bd) indefinitely following relief of obstructive jaundice. Monthly measurements of the tumour marker CA 19-9 were
used as an indicator of disease response and activity. CA 19-9 levels dropped sharply and stayed low in the two patients who
appeared to respond. Mean survival of the four patients was 21.5 months (range 4–48 months). Side effects were well
tolerated. A more extensive and detailed examination of MMP inhibitors to treat cholangiocarcinoma is indicated.
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Introduction
Cholangiocarcinoma is increasing in incidence, with
approximately 1000 new cases presenting each year in
England and Wales [1]. Only surgical resection offers
the chance of long-term disease-free survival, yet of
those patients who undergo operation, only 10%
receive a ‘curative’ resection. Mean survival of patients
with unresectable cholangiocarcinoma is 8 months
when jaundice is relieved by operative palliation and
5 months in those treated with a biliary endoprosthesis
[2]. The role of chemotherapy and radiotherapy
remains unclear in the therapeutic as well as the
adjuvant setting.
Matrix metalloproteinases (MMPs) are a function-
ally defined family of powerful enzymes, the main
action of which is the degradation of the extracellular
matrix [3]. They have important roles in wound heal-
ing, pregnancy and parturition, bone resorption and
mammary involution [4]. Scientific focus has concen-
trated on certain disease states in which breakdown of
the extracellular matrix is a key feature, e.g. rheuma-
toid arthritis, periodontal disease and cancer.
The process involved in the metastatic cascade
(breakdown of the basement membrane, invasion of
surrounding stroma, vascular invasion and extravasa-
tion at distant sites) involves proteolysis and remodel-
ling of the extracellular matrix. MMPs have been
implicated in this process [3]. Tissue inhibitors of
matrix metalloproteinases (TIMPs) are important in
maintaining a balance between matrix synthesis and
degradation caused by MMPs and therefore are found
whenever MMPs are present. Factors produced by
cancer cause a larger over-expression of MMPs as
compared with TIMPs.
In cholangiocarcinoma MMPs have been demon-
strated within both tumour cells and the stroma, and
their expression is stronger in cases of extensive tumour
invasion [5], suggesting that MMPs may play an
important role in the degradation of extracellular
matrix and facilitate cholangiocarcinoma invasion.
Marimastat (BB-2516) is a synthetic low molecular
weight MMP inhibitor (MMPI). It also has angio-
genesis inhibiting properties. Marimastat often induces
a fibroblastic matrix reaction, which makes monitoring
tumour responsiveness to the drug difficult by standard
radiological means. The tumour-associated antigen
CA 19-9 is elevated in cholangiocarcinoma [6], but it
may also be elevated in the presence of obstructive
jaundice and cholangitis (100–1000 U/ml) [7], and its
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serum measurement therefore needs to be considered
in combination with tests of liver function. It is
postulated that a fall in serum CA 19-9 may reflect
decreased tumour cell burden.
Materials and methods
Four men (median age 61; range 48–65 years) with
histologically proven stage IV cholangiocarcinoma
were offered compassionate treatment with oral
Marimastat. Treatment was universally accepted,
commenced immediately after surgical or endoscopic
intervention, and continued until death. Patient selec-
tion was a clinical decision based on certain criteria;
notably a life expectancy of43 months and the relief of
jaundice. Tumour characteristics precluding curative
resection were bilateral liver and portal vein invasion
(patient 1), multiple small hepatic metastases (patient
2), hepatic artery encasement (patient 3) and tumour
extension into the hepato-duodenal ligament (patient
4). Palliative bypass procedures were performed on
the first three patients, while the fourth patient
underwent percutaneous insertion of a metal stent.
Blood tests were performed at 1–3-monthly intervals
during follow-up. The initial dose of Marimastat was
10 mg twice daily. Side effects – predominantly upper
limb joint stiffness, pain, and swelling – occasionally
enforced dose reduction to 10 mg once daily. In severe
episodes temporary cessation of treatment for 1 week
was deemed necessary on one occasion in patient 4 and
on two occasions in patient 2.
Results
Monthly CA 19-9 measurements are shown in
Figure 1. Elevated bilirubin levels, which occurred four
times, did not cause an elevation of CA 19-9 levels
(data not shown). CA 19-9 levels of patients 1 and 2
did not significantly alter during the treatment
period. However, CA 19-9 levels of patients 3 and 4
dropped within 1 month by 14165 U/ml (to 0.4% of
original value) and 398 U/ml (31% of original value),
respectively, after commencement of Marimastat
treatment. In these latter patients these reduced CA
19-9 levels were maintained for 25 and 48 months,
respectively.
There was no serious co-morbidity, and none of the
patients experienced procedure-related complications.
The quality of life on Marimastat was good for patients
3 and 4, who were only affected by their disease close to
death. Patient 4 took a short holiday within 6 weeks of
his death. Patient 1 survived for 4 months, patient
2 for 8 months, patient 3 for 26 months and patient
4 for 48 months. Repeat axial imaging of patient 4
within a month of his death indicated progression
of disease at the hilum of the liver. There were no
histological differences between the four patients in
this study.
Discussion
Obstructive jaundice was surgically or endoscopically
resolved in all four patients immediately before Mari-
mastat treatment and may well have contributed to the
fall in CA 19-9. However, after resolution of obstruc-
tive jaundice and commencement of Marimastat
treatment, CA 19-9 levels in patients 1 (70% rise) and
2 (20% drop) did not mirror those in patients 3 and 4.
Furthermore, one episode of cholangitis in patient 3 at
14 months and two episodes of stent blockage in
patient 4 at 6 and 15 months did not appreciably affect
CA 19-9 levels.
Figure 1. Monthly CA 19-9 levels of patients 1–4.
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The dose of 20 mg daily has been shown to be
sufficiently high to ensure that mean trough levels of
Marimastat exceed the desired levels (40 mg/ml) [8],
while causing minimal treatment disruption due to side
effects and drug holidays.
Survival of patients 1 and 2 (4 and 8 months,
respectively) is consistent with the expected prognosis
of patients with this stage of disease [2]. Patients 3 and
4 show an extended survival (26 and 48 months,
respectively) from the expected. Survival of palliated
patients above 2 years is rarely reported [9].
Phase II studies of the MMPI Marimastat have
shown early promise in the treatment of colorectal,
ovarian and prostate cancer. Six studies have been
completed, and pooled analysis has demonstrated a
dose-dependent biological effect using tumour
markers as surrogate indicators of anti-tumour activity.
Effects on tumour markers were associated with
increased survival [10]. Recent phase III studies have
shown survival benefit in glioblastoma multiforme
[11], malignant melanoma [12] and inoperable gastric
cancer [13]. In the encouraging latter study there was
histological evidence of fibroblastic matrix develop-
ment. The use of an MMPI to treat unresectable
cholangiocarcinoma has not been reported previously.
It is postulated that treatment with Marimastat has
contributed to the longevity of patients 3 and 4. A
reduction in tumour MMP activity will lessen the
capability of the primary tumour to extend locally,
regionally and remotely. This negative effect on
aggressive activity may result in the observed extended
survival. The lack of apparent response in patients 1
and 2 could be due to differing MMP profiles between
individuals.
Further studies are needed to address this observa-
tion. Larger numbers should be incorporated with
frozen tumour tissue available for protein load and
enzyme activity analysis. Further results could support
and extend this exciting observation and provide
scientific backing for this treatment option.
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